These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 16920290)

  • 1. A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system.
    Dokoumetzidis A; Macheras P
    Int J Pharm; 2006 Sep; 321(1-2):1-11. PubMed ID: 16920290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension.
    Lennernäs H; Abrahamsson B
    J Pharm Pharmacol; 2005 Mar; 57(3):273-85. PubMed ID: 15807982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): theoretical basis and practical examples.
    Papadopoulou V; Valsami G; Dokoumetzidis A; Macheras P
    Int J Pharm; 2008 Sep; 361(1-2):70-7. PubMed ID: 18614303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications.
    Kawabata Y; Wada K; Nakatani M; Yamada S; Onoue S
    Int J Pharm; 2011 Nov; 420(1):1-10. PubMed ID: 21884771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical product development technologies based on the biopharmaceutical classification system.
    Jain D; Pathak D; Pathak K
    Pharmazie; 2009 Aug; 64(8):483-90. PubMed ID: 19746834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biopharmaceutical classification system--experimental model of the prediction of drug bioavailability].
    Golovenko NIa; Borisiuk IIu
    Biomed Khim; 2008; 54(4):392-407. PubMed ID: 18988456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro - in vivo correlation: from theory to applications.
    Emami J
    J Pharm Pharm Sci; 2006; 9(2):169-89. PubMed ID: 16959187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical and biopharmaceutical quality of a sustained release carbamazepine preparation: a contribution to quality assurance.
    Grunwald F; Czaja J; Düsing R; Schulz HU
    Int J Clin Pharmacol Ther Toxicol; 1992 May; 30(5):160-6. PubMed ID: 1592543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS): Beyond guidelines.
    Charalabidis A; Sfouni M; Bergström C; Macheras P
    Int J Pharm; 2019 Jul; 566():264-281. PubMed ID: 31108154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Very rapid dissolution is not needed to guarantee bioequivalence for biopharmaceutics classification system (BCS) I drugs.
    Kortejärvi H; Shawahna R; Koski A; Malkki J; Ojala K; Yliperttula M
    J Pharm Sci; 2010 Feb; 99(2):621-5. PubMed ID: 19844950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solid dispersions, part I: recent evolutions and future opportunities in manufacturing methods for dissolution rate enhancement of poorly water-soluble drugs.
    Bikiaris DN
    Expert Opin Drug Deliv; 2011 Nov; 8(11):1501-19. PubMed ID: 21919807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probability of passing dissolution acceptance criteria for an immediate release tablet.
    Dumont ML; Berry MR; Nickerson B
    J Pharm Biomed Anal; 2007 May; 44(1):79-84. PubMed ID: 17379465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biopharmaceutical classification based on solubility and dissolution: a reappraisal of criteria for hypothesis models in the light of the experimental observations.
    Charkoftaki G; Dokoumetzidis A; Valsami G; Macheras P
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):168-72. PubMed ID: 20030634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of biopharmaceutical parameters in drug development (author's transl)].
    Thoma K
    Arzneimittelforschung; 1976; 26(1A):121-9. PubMed ID: 947191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates.
    Kortejärvi H; Urtti A; Yliperttula M
    Eur J Pharm Sci; 2007 Feb; 30(2):155-66. PubMed ID: 17187967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solubility behavior and biopharmaceutical classification of novel high-solubility ciprofloxacin and norfloxacin pharmaceutical derivatives.
    Breda SA; Jimenez-Kairuz AF; Manzo RH; Olivera ME
    Int J Pharm; 2009 Apr; 371(1-2):106-13. PubMed ID: 19150493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The utility of cyclodextrins for enhancing oral bioavailability.
    Carrier RL; Miller LA; Ahmed I
    J Control Release; 2007 Nov; 123(2):78-99. PubMed ID: 17888540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of Choice of Solubility and Dissolution Media After Two Decades of Biopharmaceutical Classification System.
    Bou-Chacra N; Melo KJC; Morales IAC; Stippler ES; Kesisoglou F; Yazdanian M; Löbenberg R
    AAPS J; 2017 Jul; 19(4):989-1001. PubMed ID: 28516359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory aspects of drug dissolution from a European perspective.
    Graffner C
    Eur J Pharm Sci; 2006 Nov; 29(3-4):288-93. PubMed ID: 16950606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fast-dissolving microparticles fail to show improved oral bioavailability.
    Wong SM; Kellaway IW; Murdan S
    J Pharm Pharmacol; 2006 Oct; 58(10):1319-26. PubMed ID: 17034654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.